CEL-SCI (NYSE:CVM) Stock Price Up 8% - Time to Buy?

Key Points

• CEL-SCI Co. shares rose 8% to $9.94, with a notable trading volume decline of 45% compared to the average.
• CEO Geert R. Kersten recently purchased 29,197 shares at $6.85 each, significantly increasing his ownership stake in the company.
• MAI Capital Management raised its stake in CEL-SCI by 229.9%, acquiring an additional 366,880 shares in the first quarter.

CEL-SCI Co. (NYSE:CVM - )'s share price rose 8% during mid-day trading on Wednesday . The company traded as high as $10.42 and last traded at $9.94. Approximately 193,893 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 352,052 shares. The stock had previously closed at $9.20.

CEL-SCI Stock Up 8.0%

The stock has a 50 day moving average price of $9.29 and a 200 day moving average price of $6.61. The stock has a market capitalization of $68.41 million, a price-to-earnings ratio of -20.71 and a beta of 0.54. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66.

Insider Activity at CEL-SCI

In other news, CEO Geert R. Kersten purchased 29,197 shares of the business's stock in a transaction dated Friday, July 25th. The shares were purchased at an average cost of $6.85 per share, with a total value of $199,999.45. Following the completion of the purchase, the chief executive officer owned 72,835 shares of the company's stock, valued at $498,919.75. This trade represents a 66.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 14.06% of the company's stock.

Hedge Funds Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. MAI Capital Management increased its stake in CEL-SCI Co. (NYSE:CVM - Free Report) by 229.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 526,480 shares of the company's stock after acquiring an additional 366,880 shares during the quarter. MAI Capital Management owned about 0.63% of CEL-SCI worth $121,000 at the end of the most recent reporting period. 12.08% of the stock is currently owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.